Impact Biomedical Inc. is a majority owned subsidiary of DSS, Inc. The company has technology assets for licensing and partnering, products for distribution and sales, and strategic investments in healthcare.

Impact Biomedical Inc. provides unique technology provider and business capabilities in addressing unmet needs in human healthcare and wellness.

in the pipeline

Biotech / Med-Tech

(FDA/EMA Regulated)

Consumer Wellness


Technologies / Products

Core Technologies

Summary: Impact Biomedical FDA / MedTech Pipeline U.S.

Asset Preclinical Ph I Ph II Ph III Approved IP Description
LineBacker 2029/2036 Small molecule x-bonded polyphenol compounds with potential application in neurological and inflammatory disorders.

Technologies / Products

Core Technologies

Summary : Impact Biomedical OTC/Consumer U.S.

Asset Development Clinical/efficacy stydy
  • U.S. clinical study(upper respiratory infections) due 2/3Q 2023: OTC application.
  • Expand Linebacker platform.
  • Preclinical studies/establish new intellectual property.
  • U.S. launch planned 4Q23:1Q24.
  • Confirmation studies insect protection/antimicrobial.
  • Confirmation studies insect protection/antimicrobial.
  • Confirmation studies: beta protective effect.
  • Study data to be provided to U.S. Patent Office.